HLB Panagen has rapidly expanded its precision diagnostic lineup beyond cancer diagnosis to include infectious diseases such as respiratory infections, completing preparations for global expansion. In addition to HLB Panagen's cancer diagnostic products, its subsidiary Biosquare has established a full lineup of respiratory diagnostic products, targeting the global market worth 10 trillion KRW.
Concrete achievements are following. On the 2nd, Biosquare, a subsidiary of HLB Panagen, received approval from the Ministry of Food and Drug Safety for an in vitro diagnostic medical device for RSV (Respiratory Syncytial Virus).
RSV is an acute respiratory infection virus that occurs most frequently from autumn to early spring. It poses a high risk of progressing to pneumonia if infants and the elderly become infected, making early diagnosis essential. Since its symptoms are generally similar to those of the common cold, precise diagnosis is required.
The product approved for Biosquare applies quantum dot technology to achieve the highest level of precision. The nano-particle quantum dots were developed based on Biosquare's QuantumPACK platform. Following the approval of influenza A/B and COVID-19 diagnostic devices, this approval for respiratory infectious diseases further demonstrates high technological capability. It is also significant that Biosquare now has a complete basic product lineup for respiratory infectious diseases.
For global expansion, Biosquare is preparing the sales procedures for these products in the United States and plans to seek entry into Europe by obtaining European certification (CE) for RSV, as it has for the certified influenza A/B and COVID-19 products. Production of the proprietary analysis equipment (QDITS) developed in-house is also increasing.
Once exports become tangible, both diagnostic devices and analysis equipment are expected to see increased sales.
HLB Panagen plans to grow into a global-level diagnostic company covering the entire diagnostic field from prediction to diagnosis by combining its cancer diagnostic technology with Biosquare’s respiratory diagnostics and Arontier’s AI diagnostic technology.
Jang In-geun, CEO of HLB Panagen, said, “We have completed preparations for full-scale growth by completing the respiratory immune diagnostic panel using Biosquare’s quantum dot-based platform technology.” He added, “HLB Panagen will expand its business area into AI diagnostics in addition to completing traditional molecular and immune diagnostic platforms, growing into a total solution service company in the diagnostic field.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
